Acute Infection, Sepsis
Conditions
Keywords
MMP, Matrix metalloproteinase, Metabolomics, FGF-21, Quick SOFA, Infection, Triage
Brief summary
Adult patients with suspected or confirmed infection and who will be sampled for blood culture will be recruited. Blood samples are collected for the analysis of matrix metalloproteinases (MMP) and their inhibitors. We also aim to analyse metabolic changes and use the samples for analysis of blood lactate, metabolomics, and fibroblast growth factor 21 (FGF-21) as well. The primary aim of the study is to test the performance of MMP-8 in finding severely ill patients who will need treatment in high dependency unit or intensive care. The secondary aim is to study the metabolic changes in acutely ill patients with infection.
Detailed description
Adult patients with suspected or confirmed infection and who will be sampled for blood culture (a surrogate for suspected severe infection) will be recruited from three large emergency departments in a University hospital. Two blood samples will be collected: one for the analysis of matrix metalloproteinases, their inhibitor tissue inhibitor of metalloproteinase-1 (TIMP-1), FGF-21 and metabolomic analyses. Another blood sample is for the analysis of blood lactate. Clinical data will be collected to calculate quick SOFA (qSOFA), in order to test whether lactate and/or MMP-8 will improve the prognostic model if they are added to qSOFA. The primary outcome measure is the number of days alive without the need for ICU or high dependency unit treatment. The ability of MMP-8 to discriminate severe infection from uneventful course of the disease will be studied. The secondary aim is to study the metabolic changes in acutely ill patients with infection and compare these variables between survivors and non-survivors. The planned number of patients recruited is 924. During this study the feasibility of a bedside rapid analysis of MMP-8 will be tested in 30 patients and the results obtained using the rapid analyser compared with laboratory results obtained using ELISA.
Interventions
None listed
Sponsors
University of Helsinki
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Age 18 or more Suspected or confirmed infection Admitted to any of the three emergency departments of university hospital Decision of blood culture
Exclusion criteria
Age \<18 Cancer with metastases Decision of treatment limitation probable or made Consent not obtainable
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Days alive without intensive care or high dependency unit treatment | 2 weeks from study admission | Accounts for patients who survive and need no ICU or high dependency care for the primary infection. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| 30 day mortality | 30 days | Number of patients who die within 30 days of admission |
| 90 day mortality | 90 days | Number of patients who die within 90 days aof admission |
Countries
Finland
Outcome results
None listed